How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies. More sophisticated molecules coupled with increasingly complex trial designs “leads to a lot of complexity to deal with.
110 
Let's personalize your content